Exicure, Inc.
8045 Lamon Avenue
Suite 410
Skokie
Illinois
60077
United States
Tel: 847-673-1700
Fax: 847-556-6411
Website: http://www.exicuretx.com/
124 articles with Exicure, Inc.
-
Exicure, Inc. Announces $11.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
12/14/2021
The gross proceeds to the Company from this offering are expected to be approximately $11.5 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
-
Exicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus
12/10/2021
Exicure, Inc.® announced the results of its previously disclosed independent internal investigation and a number of strategic actions aimed to reduce cash spend and prioritize the Company’s therapeutic pipeline.
-
Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress
11/19/2021
Exicure, Inc. today reported financial results for the quarter ended September 30, 2021 and provided an update on corporate progress.
-
Exicure to Present at Upcoming Scientific Conferences - Oct 28, 2021
10/28/2021
Exicure, Inc.®, a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced presentations at the following scientific conferences during the month of November:
-
Exicure to Present at Upcoming Scientific Conferences
10/7/2021
Exicure , Inc. today announced presentations in the following scientific conferences during the month of October: 17th International Congress on Neuronal Ceroid Lipofuscinosis (NCLs)
-
Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
10/4/2021
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021.
-
Exicure to Present at the Benzinga Healthcare Small Cap Conference
9/23/2021
Exicure , Inc today announced that CEO David Giljohann will present at the Benzinga Healthcare Small Cap Conference on Thursday, September 30, 2021, at 3:20 PM ET.
-
Exicure to Participate in Upcoming Scientific Conferences
9/15/2021
Exicure , Inc. today announced participation in the following scientific conferences during the month of September: TIDES USA 2021 Poster presentation: "Biodistribution of Spherical Nucleic Acids in the Rat CNS Following ICM and IT Delivery" September 20 – 30, 2021
-
Exicure to Participate in Upcoming Investor Conferences
9/1/2021
Exicure , Inc. today announced participation in the following investor conferences during the month of September: Citi’s 16th Annual Biopharma Conference 2021 One-on-one meetings September 8-10, 2021
-
While treatments exist to manage the symptoms of the disease, nothing has proven to be curative – yet. Several biopharma companies are working hard to change that.
-
Exicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate Progress
8/12/2021
Exicure, Inc. today reported financial results for the quarter ended June 30, 2021 and provided an update on corporate progress.
-
Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)
8/5/2021
Exicure, Inc. is providing an update on the Phase 1b/2 clinical trial of cavrotolimod (AST-008) (NCT03684785).
-
Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference
8/4/2021
Exicure , Inc. today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:30pm ET. Exicure will also host 1x1 investor meetings during the conference.
-
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
8/2/2021
Ipsen and Exicure Inc. have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids as potential investigational treatments for Huntington’s disease and Angelman syndrome.
-
The deal will see Ipsen and Exicure collaborating to research, develop, and commercialize Spherical Nucleic Acids to treat AS and HD.
-
Exicure Announces Upcoming Neuroscience Pipeline Update at Virtual R&D Day
7/8/2021
Exicure, Inc. will host a virtual R&D Day on Thursday, July 15, 2021 from 10:00 am to 11:00 am ET.
-
Exicure, Inc. to Present at Ladenburg Thalmann 2021 Healthcare Conference
6/29/2021
Exicure, Inc.®, a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced that CEO David Giljohann will present a company update as well as participate in a series of 1x1 meetings at the Ladenburg Thalmann 2021 Healthcare Conference occurring July 13-14, 2021.
-
Exicure, Inc. Announces Participation in Upcoming Conferences
6/3/2021
Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will participate in the following upcoming conferences: BIO Digital 2021 Format : Corporate update presentation Date : June 10, 2021 Time : 7:00 AM ET
-
Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)
5/13/2021
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointment of Brian C. Bock as the Company’s Chief Financial Officer (CFO) effective immediately.
-
Exicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress
5/12/2021
Company Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients With Unmet Medical Needs